Company Profile
Hangzhou Merryhealth Biotechnology Co., Ltd. is a China-based manufacturer of circulating tumor cell detection systems and liquid biopsy solutions, headquartered in Hangzhou, Zhejiang, China. Founded in July 2019, the company operates as an independent private entity, serving clinical laboratories, oncology departments, and research institutions across China.
Core Products & Technologies
CTC Detection Systems
• TC-seeker Circulating Tumor Cell Detection Kit: Proprietary immunomagnetic positive-enrichment reagent for CTC isolation from peripheral blood, with capture efficiency ~40% higher than conventional methods
• TC Trapper Cell Capture Instrument: Compact, automated cell-capture device integrating intelligent sensing for streamlined CTC enrichment workflows
• Cell Counter: Fluorescence-based enumeration system for precise CTC quantification post-capture
Clinical Diagnostic Services
• Independent Medical Laboratory: CAP-compliant testing facility in Hangzhou offering CTC enumeration and molecular analysis for cancer patients
• Sequencing Integration Service: End-to-end CTC capture-to-sequencing workflow supporting single-cell transcriptomic studies
Market Position & Certifications
Merryhealth holds a niche position in China's domestic CTC liquid-biopsy market, competing with Menarini Silicon Biosystems and Qiagen. Key strengths include:
• Positive-enrichment capture technology: Proprietary magnetic-bead-free approach preserving CTC viability for downstream molecular analysis
• Regulatory compliance: NMPA Class I medical device production filing (Zhejiang Hangzhou No. 20230015), ISO 9001 and ISO 13485 quality systems, EU CE marking, and zero-deficiency FDA inspections
• Academic validation: CTC capture technology cited in Cancer Cell (2023) by Sichuan University West China Hospital researchers
• Full vertical integration: In-house R＆D, GMP-level production, and clinical testing services under one roof
Corporate Timeline
2019 — Established in Hangzhou to commercialize CTC detection technologies
2021 — Expanded operations and updated corporate contact infrastructure
2023 — Granted NMPA Class I medical device production filing for IVD reagents and sample-separation equipment
2023 — TC capture and sequencing-integration technology featured in peer-reviewed Cancer Cell publication on CTC immune-evasion mechanisms
Target Markets & Applications
• Early Cancer Screening: CTC enumeration for asymptomatic high-risk population surveillance
• Treatment Guidance: Real-time CTC monitoring to inform personalized chemotherapy and immunotherapy decisions
• Post-Operative Surveillance: Serial CTC testing for recurrence monitoring after surgical resection
• Translational Research: CTC-derived single-cell sequencing for tumor heterogeneity and metastasis studies
Contact Information
Global Headquarters
Address: Room 203, Building 7, No. 368, 12th Avenue, Baiyang Street, Hangzhou Economic and Technological Development Zone, Zhejiang, China
Tel: +86-13911465491
Email: marryhealth@163.com
Website: merryhealthbio.com
Corporate Structure
Hangzhou Merryhealth Biotechnology Co., Ltd. operates as an independent private enterprise with no publicly traded parent company.
Legal Representative: Xu Qiang
Registered Capital: RMB 500,000
Unified Social Credit Code: 91330101MA2GNNNQ2M
Investor Relations: Not applicable — privately held company with no publicly traded stock.
